Shearman & Sterling represented BofA Merrill Lynch, Morgan Stanley, Barclays Capital and Deutsche Bank as joint book-running managers and representatives of the several managers in connection with Amgen’s offering of €550,000,000 4.375% Senior Notes due 2018 and £475,000,000 5.50% Senior Notes due 2026. The offering was conducted in accordance with Regulation S.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The following Shearman & Sterling team advised the managers in the transaction: partners John Wilson (San Francisco-Capital Markets), Lisa Jacobs (New York-Capital Markets) and Larry Crouch (Palo Alto-Tax); counsel Jung-Kyu McCann (Palo Alto-Capital Markets); and associates Phillip Monk (Palo Alto-Capital Markets), Christina Leto (London-Capital Markets) and Anil Kalia (Palo Alto-Tax).

 

www.shearman.com

|



Related Posts:



Leave a Reply